12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Myrbetriq regulatory update

EMA's CHMP recommended approval of an MAA from Astellas for Betmiga mirabegron from Astellas to treat overactive bladder...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >